EU Regulatory Affairs Flashcards

1
Q

What are key responsibilities of regulatory professionals?

A

Interpret regulations, identify compliance risks, lead HA interactions, support product launches and MA maintenance.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Name three key EU regulatory bodies.

A

EMA, HMA, National Competent Authorities (NCAs).

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

What are the four types of Marketing Authorisation (MA) procedures in the EU?

A

National, Decentralised (DCP), Mutual Recognition (MRP), Centralised (CP).

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

What is unique about the Centralised Procedure (CP)?

A

Single EMA-led approval valid across all EU states (except UK), Iceland, Liechtenstein, Norway.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

What is the purpose of the Target Product Profile (TPP)?

A

Define ideal product characteristics, align regulatory/commercial strategies, aid submission planning.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

List key components of a TPP.

A

Description, indication, patient population, dosage, storage, clinical/safety, regulatory, commercial, IP.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Why is EMA scientific advice important?

A

Ensures alignment with regulatory expectations and reduces risk of submission failure.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

When should scientific advice be sought?

A

For innovative therapies, SMEs, or deviations from guidelines.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Name 3 EU expedited pathways and their benefits.

A

PRIME: early support; Accelerated Assessment: 150-day review; CMA: early approval + confirmatory trials.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

What are Adaptive Pathways?

A

Stepwise approvals based on RWE for gradual indication expansion.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

What are incentives for Orphan Drug Designation?

A

10 years exclusivity (plus 2 if paediatric), fee reductions.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

What are benefits of a Paediatric Investigation Plan (PIP)?

A

6-month SPC extension, 10-year protection under PUMA.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

What does the MAA include?

A

Modules 1–5 of the CTD (Common Technical Document).

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

What are the responsibilities of an EU Regulatory Lead during MAA?

A

HA engagement, global messaging alignment, brand name management, submission timeline oversight.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

What are the three variation types under EU Regulation 1234/2008?

A

Type IA/IAIN (minor), Type IB (moderate), Type II (major).

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

How can variation approvals be streamlined?

A

Group related changes and use workshare procedures.

17
Q

What are goals of upcoming EU pharma legislation reforms?

A

Boost R&D, ensure equitable access, address AMR and supply chain resilience.

18
Q

What is essential for EU regulatory success?

A

Strategic alignment, planning, use of expedited pathways, lifecycle management, HTA awareness.